Aurinia Pharmaceuticals Inc. (AUPH)
AUPH Stock Price Chart
Explore Aurinia Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze AUPH price movements and trends.
AUPH Company Profile
Discover essential business fundamentals and corporate details for Aurinia Pharmaceuticals Inc. (AUPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Sept 2014
Employees
130.00
Website
https://www.auriniapharma.comCEO
Kevin C. Tang
Description
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
AUPH Financial Timeline
Browse a chronological timeline of Aurinia Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $0.21, while revenue estimate is $80.94m.
Earnings released on 7 May 2026
EPS came in at $0.25 surpassing the estimated $0.18 by +38.89%, while revenue for the quarter reached $77.71m , beating expectations by +0.94%.
Earnings released on 26 Feb 2026
EPS came in at $0.26 surpassing the estimated $0.21 by +23.81%, while revenue for the quarter reached $77.11m , beating expectations by +3.24%.
Earnings released on 4 Nov 2025
EPS came in at $0.23 surpassing the estimated $0.16 by +43.75%, while revenue for the quarter reached $73.47m , beating expectations by +8.51%.
Earnings released on 31 Jul 2025
EPS came in at $0.16 falling short of the estimated $0.17 by -5.88%, while revenue for the quarter reached $70.01m , beating expectations by +9.73%.
Earnings released on 12 May 2025
EPS came in at $0.16 surpassing the estimated $0.08 by +100.00%, while revenue for the quarter reached $62.47m , beating expectations by +2.21%.
Earnings released on 27 Feb 2025
EPS came in at $0.09 surpassing the estimated $0.03 by +200.00%, while revenue for the quarter reached $59.87m , missing expectations by -0.41%.
Earnings released on 7 Nov 2024
EPS came in at $0.10 surpassing the estimated $0.02 by +400.00%, while revenue for the quarter reached $67.77m , beating expectations by +17.90%.
Earnings released on 1 Aug 2024
EPS came in at $0.02 surpassing the estimated $0.01 by +100.00%, while revenue for the quarter reached $57.19m , beating expectations by +5.42%.
Earnings released on 2 May 2024
EPS came in at -$0.03 surpassing the estimated -$0.17 by +82.35%, while revenue for the quarter reached $50.30m , beating expectations by +6.86%.
Earnings released on 15 Feb 2024
EPS came in at -$0.19 falling short of the estimated -$0.18 by -5.56%, while revenue for the quarter reached $45.10m , beating expectations by +0.21%.
Earnings released on 2 Nov 2023
EPS came in at -$0.09 surpassing the estimated -$0.17 by +47.06%, while revenue for the quarter reached $54.52m , beating expectations by +41.82%.
Earnings released on 3 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.20 by +60.00%, while revenue for the quarter reached $41.49m , beating expectations by +9.49%.
Earnings released on 4 May 2023
EPS came in at -$0.18 surpassing the estimated -$0.24 by +25.00%, while revenue for the quarter reached $34.41m , beating expectations by +23.44%.
Earnings released on 28 Feb 2023
EPS came in at -$0.18 surpassing the estimated -$0.26 by +30.77%, while revenue for the quarter reached $28.44m , beating expectations by +2.38%.
Earnings released on 3 Nov 2022
EPS came in at -$0.06 surpassing the estimated -$0.18 by +66.67%, while revenue for the quarter reached $55.78m , beating expectations by +54.15%.
Earnings released on 4 Aug 2022
EPS came in at -$0.25 falling short of the estimated -$0.22 by -13.64%, while revenue for the quarter reached $28.19m , beating expectations by +4.25%.
Earnings released on 10 May 2022
EPS came in at -$0.27 falling short of the estimated -$0.26 by -3.85%, while revenue for the quarter reached $21.63m , beating expectations by +12.45%.
Earnings released on 28 Feb 2022
EPS came in at -$0.25 surpassing the estimated -$0.26 by +3.85%, while revenue for the quarter reached $23.40m , beating expectations by +6.41%.
Earnings released on 3 Nov 2021
EPS came in at -$0.39 falling short of the estimated -$0.31 by -25.81%, while revenue for the quarter reached $14.67m , beating expectations by +36.57k%.
Earnings released on 5 Aug 2021
EPS came in at -$0.37 falling short of the estimated -$0.35 by -5.71%, while revenue for the quarter reached $6.62m , beating expectations by +16.45k%.
AUPH Stock Performance
Access detailed AUPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
